Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
Anthony SebbaClifton O BinghamVivian P BykerkStefano FioreKerri FordJud C JanakDimitrios A PappasTaylor BlachleySwapna S DaveJoel M KremerMiao YuErnest H S ChoyPublished in: Clinical rheumatology (2023)
This observational study showed no significant differences in outcomes among b/ts-experienced TNFi vs IL-6Ri initiators, as either mono- or combination therapy. These findings were in contrast with the previous RCTs in biologic-naïve patients and could be explained by the differences in the patient characteristics included in this study. Further studies are needed to help understand the reasons for this discrepancy in the real-world b/ts-experienced population.
Keyphrases
- combination therapy
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- magnetic resonance
- prognostic factors
- randomized controlled trial
- patient reported outcomes
- high dose
- computed tomography
- interstitial lung disease
- idiopathic pulmonary fibrosis
- patient reported